tiprankstipranks
Trending News
More News >

Dr. Reddy’s Laboratories to Engage with Investors in Hyderabad Meetings

Story Highlights
  • Dr. Reddy’s Laboratories announced participation in investor conferences on June 20, 2025.
  • The meetings aim to enhance transparency and investor relations through in-person engagements.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Dr. Reddy’s Laboratories to Engage with Investors in Hyderabad Meetings

Don’t Miss TipRanks’ Half-Year Sale

Dr Reddy’s Laboratories ( (RDY) ) has shared an update.

On June 20, 2025, Dr. Reddy’s Laboratories announced its participation in upcoming investor conferences scheduled for June 25 and 26, 2025, in Hyderabad. These meetings, organized by B&K Securities and Avendus Spark, are set to be in-person group meets, providing an opportunity for the company’s management to engage with institutional investors. This engagement is part of Dr. Reddy’s ongoing efforts to maintain transparency and communication with stakeholders, potentially impacting investor relations and market perceptions positively.

The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

Dr Reddy’s Laboratories’ strong financial performance is the most significant factor, underscored by consistent revenue growth and profitability. Technical analysis supports a favorable stock trend, although valuation is fair with modest income potential. The absence of earnings call and corporate events data did not impact the overall score.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories is a prominent pharmaceutical company based in Hyderabad, India. It specializes in the development and manufacturing of a wide range of pharmaceutical products, focusing on generic medications, active pharmaceutical ingredients (APIs), and proprietary products. The company is listed on major stock exchanges, including the National Stock Exchange of India, BSE Limited, and the New York Stock Exchange.

Average Trading Volume: 2,114,557

Technical Sentiment Signal: Strong Buy

Current Market Cap: $12.64B

For an in-depth examination of RDY stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1